The United States’ health care system saved $25.5 billion between 2005 and 2012 due to patent settlements that moved generic pharmaceuticals to market in advance of brand-name drugs’ patent expiration date, according to research financed by generic drug manufacturers.
The “Impact of Patent Settlements on Drug Costs: Estimation of Savings” study was released on Tuesday by the IMS Institute for Healthcare Informatics, which studied 33 settlements on behalf of the Generic Pharmaceutical Association.
